Thymidine-phosphorothioate oligonucleotides induce activation and apoptosis of CLL cells independently of CpG motifs or BCL-2 gene interference

被引:0
作者
J E Castro
C E Prada
R A Aguillon
S Kitada
T Fukuda
M Motta
C Wu
F Dicker
G Sun
J Y J Wang
D A Carson
J C Reed
T J Kipps
机构
[1] John and Rebecca Moores Cancer Center,Department of Biology
[2] University of California San Diego,Department of Leukemia
[3] The Burnham Institute,undefined
[4] University of California San Diego,undefined
[5] Chronic lymphocytic leukemia Research Consortium (C.R.C),undefined
[6] MD Anderson Cancer Center,undefined
来源
Leukemia | 2006年 / 20卷
关键词
apoptosis; leukemia; oligonucleotides; CpG motifs; Bcl-2;
D O I
暂无
中图分类号
学科分类号
摘要
We compared antisense phosphorothioate oligonucleotides (PS-ODN) that target BCL-2 such as Genasense® (G3139-PS), with other PS-ODN or phosphodiester-ODN (PO-ODN) in their relative capacity to induce apoptosis of chronic lymphocytic leukemia (CLL) B cells in vitro. Surprisingly, we found that thymidine-containing PS-ODN, but not PO-ODN, induced activation and apoptosis of CLL cells independent of BCL-2 antisense sequence or CpG motifs. All tested thimidine-containing PS-ODN, irrespective of their primary sequences, reduced the expression of Bcl-2 protein and increased the levels of the proapoptotic molecules p53, Bid, Bax in CLL cells. Apoptosis induced by thymidine-containing PS-ODN was preceded by cellular activation, could be blocked by the tyrosine-kinase inhibitor imatinib mesylate (Gleevec®), and was dependent on ABL kinase. We conclude that thymidine-containing PS-ODN can activate CLL cells and induce apoptosis via a mechanism that is independent of BCL-2 gene interference or CpG motifs.
引用
收藏
页码:680 / 688
页数:8
相关论文
共 212 条
[31]  
Edelman MJ(1999) by a 2-phenylaminopyrimidine derivative Br J Haematol 107 611-3206
[32]  
Karnauskas R(2004)High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry Clin Cancer Res 10 3195-65
[33]  
Tomek R(2002)Antisense-mediated suppression of Bcl-2 highlights its pivotal role in failed apoptosis in B-cell chronic lymphocytic leukaemia Trends Immunol 23 64-175
[34]  
Marcucci G(2002)Antisense RNA down-regulation of bcl-2 expression in DU145 prostate cancer cells does not diminish the cytostatic effects of G3139 (Oblimersen) Antisense Nucleic Acid Drug Dev 12 165-22
[35]  
Stock W(2003)From A to Z on CpG Cancer Cell 3 17-117
[36]  
Dai G(1999)Highly immunostimulatory CpG-free oligodeoxynucleotides for activation of human leukocytes Breast Cancer Res Treat 55 107-553
[37]  
Klisovic RB(2002)Apoptosis-targeted therapies for cancer Am J Gastroenterol 97 542-1048
[38]  
Liu S(2001)Regulation of BAX and BCL-2 expression in breast cancer cells by chemotherapy Cell Death Differ 8 1047-1060
[39]  
Klisovic MI(2003)NSAID inhibition of GI cancer growth: clinical implications and molecular mechanisms of action Eur J Cancer 39 1053-15
[40]  
Tolcher AW(2001)DNA damage and apoptosis Cancer Lett 174 1-4447